Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

2.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

3.

New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.

Seetharamu N, Preeshagul IR, Sullivan KM.

Lung Cancer (Auckl). 2017 Jul 13;8:67-78. doi: 10.2147/LCTT.S113177. eCollection 2017. Review.

4.

The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, de Marinis F.

Clin Lung Cancer. 2016 May;17(3):161-8. doi: 10.1016/j.cllc.2016.01.004. Epub 2016 Jan 28. Review.

PMID:
26908078
5.

Current state of immunotherapy for non-small cell lung cancer.

Malhotra J, Jabbour SK, Aisner J.

Transl Lung Cancer Res. 2017 Apr;6(2):196-211. doi: 10.21037/tlcr.2017.03.01. Review. Erratum in: Transl Lung Cancer Res. 2017 Oct;6(5):612.

6.

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.

Jean F, Tomasini P, Barlesi F.

Ther Adv Med Oncol. 2017 Dec;9(12):769-779. doi: 10.1177/1758834017741074. Epub 2017 Dec 19. Review.

7.

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).

Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, Dimopoulos MA.

Ann Transl Med. 2018 Apr;6(8):144. doi: 10.21037/atm.2018.02.07. Review.

8.

Actualités et perspectives concernant l’immunothérapie en oncologie thoracique.

Mignard X, Chaabane N, Fallet V, Wislez M.

Bull Cancer. 2018 Dec;105 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(18)30386-2. Review. French.

PMID:
30595194
9.

Immunotherapy in previously treated non-small cell lung cancer (NSCLC).

Leal TA, Ramalingam SS.

J Thorac Dis. 2018 Feb;10(Suppl 3):S422-S432. doi: 10.21037/jtd.2018.01.141. Review.

10.

The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.

Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q, Pei L, Cai F, Ma L, Yu Y.

Discov Med. 2018 Oct;26(143):155-166.

11.

Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.

Ellis PM, Vella ET, Ung YC.

Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16. Review.

PMID:
28416123
12.

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.

Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA.

Oncologist. 2019 Apr;24(4):563-569. doi: 10.1634/theoncologist.2018-0084. Epub 2018 Dec 12.

PMID:
30541754
13.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ.

Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22. Review.

14.

The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.

Sgambato A, Casaluce F, Gridelli C.

Expert Opin Biol Ther. 2017 May;17(5):565-571. doi: 10.1080/14712598.2017.1294157. Epub 2017 Feb 20. Review.

PMID:
28276698
15.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.

Curr Clin Pharmacol. 2018;13(2):76-84. doi: 10.2174/1574884713666180711160008.

PMID:
29992894
16.

Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.

Tan PS, Aguiar P Jr, Haaland B, Lopes G.

Lung Cancer. 2018 Jan;115:84-88. doi: 10.1016/j.lungcan.2017.11.017. Epub 2017 Nov 22.

PMID:
29290267
17.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

18.

Review of checkpoint immunotherapy for the management of non-small cell lung cancer.

Raju S, Joseph R, Sehgal S.

Immunotargets Ther. 2018 Jul 31;7:63-75. doi: 10.2147/ITT.S125070. eCollection 2018. Review.

19.

Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.

Gridelli C, Ascierto PA, Barberis MC, Felip E, Garon EB, O'brien M, Senan S, Casaluce F, Sgambato A, Papadimitrakopoulou V, De Marinis F.

Expert Opin Biol Ther. 2016 Dec;16(12):1479-1489. Epub 2016 Sep 21.

PMID:
27650132
20.

Prospects and progress of atezolizumab in non-small cell lung cancer.

Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A.

Expert Opin Biol Ther. 2017 Jun;17(6):781-789. doi: 10.1080/14712598.2017.1309389. Epub 2017 Mar 28. Review.

PMID:
28335643

Supplemental Content

Support Center